- Home
- SKBL vs ANNX Comparison
SKBL vs ANNX Comparison
Compare SKBL & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKBL
- ANNX
- Stock Information
- Founded
- SKBL 2012
- ANNX 2011
- Country
- SKBL Hong Kong
- ANNX United States
- Employees
- SKBL N/A
- ANNX N/A
- Industry
- SKBL
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- SKBL
- ANNX Health Care
- Exchange
- SKBL NYSE
- ANNX Nasdaq
- Market Cap
- SKBL 389.6M
- ANNX 362.4M
- IPO Year
- SKBL 2025
- ANNX 2020
- Fundamental
- Price
- SKBL $12.35
- ANNX $1.60
- Analyst Decision
- SKBL
- ANNX Strong Buy
- Analyst Count
- SKBL 0
- ANNX 5
- Target Price
- SKBL N/A
- ANNX $18.67
- AVG Volume (30 Days)
- SKBL 745.6K
- ANNX 1.6M
- Earning Date
- SKBL 01-01-0001
- ANNX 05-20-2025
- Dividend Yield
- SKBL N/A
- ANNX N/A
- EPS Growth
- SKBL N/A
- ANNX N/A
- EPS
- SKBL 0.03
- ANNX N/A
- Revenue
- SKBL $49,638,709.00
- ANNX N/A
- Revenue This Year
- SKBL N/A
- ANNX N/A
- Revenue Next Year
- SKBL N/A
- ANNX N/A
- P/E Ratio
- SKBL $393.54
- ANNX N/A
- Revenue Growth
- SKBL 9.58
- ANNX N/A
- 52 Week Low
- SKBL $6.93
- ANNX $1.29
- 52 Week High
- SKBL $13.50
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- SKBL N/A
- ANNX 38.84
- Support Level
- SKBL N/A
- ANNX $1.62
- Resistance Level
- SKBL N/A
- ANNX $2.01
- Average True Range (ATR)
- SKBL 0.00
- ANNX 0.13
- MACD
- SKBL 0.00
- ANNX 0.01
- Stochastic Oscillator
- SKBL 0.00
- ANNX 0.00
About SKBL SKYLINE BUILDERS GROUP HOLDING LIMI
Skyline Builders Group Holding Ltd is an holding company operates through its subsidiary. It is a Public Works Contractor company undertaking roads and drainage in Hong Kong. Its construction activities mainly include public civil engineering works, such as road and drainage works, in Hong Kong.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.